The clinical responses observed following treatment with immune checkpoint inhibitors
(ICIs) support immunotherapy as a potential anticancer treatment. However, a large …

Glioblastoma (GBM), the predominant and primary malignant intracranial tumor, poses a
formidable challenge due to its immunosuppressive microenvironment, thereby confounding …

HCC is one of the most common cancers worldwide, and the third leading cause of cancer‐
related death globally. HCC comprises nearly 90% of all cases of primary liver cancer …

Hepatocellular carcinoma (HCC) is an immunotherapy-resistant malignancy characterized
by high cellular heterogeneity. The diversity of cell types and the interplay between tumor …

Hepatocellular carcinoma (HCC) is a major health concern worldwide, with limited
therapeutic options and poor prognosis. In recent years, immunotherapies such as immune …

The success of atezolizumab plus bevacizumab treatment contributed to a shift in systemic
therapies for hepatocellular carcinoma (HCC) towards combinations that include cancer …

Immune-based therapies such as immune checkpoint inhibitors have revolutionized the
systemic treatment of various cancer types. The therapeutic application of monoclonal …

Immune associated cells in the microenvironment have a significant impact on the
development and progression of hepatocellular carcinoma (HCC) and have received more …

Background & Aims Non-alcoholic steatohepatitis (NASH) represents the fastest growing
underlying cause of hepatocellular carcinoma (HCC) and has been shown to impact …

Gut dysbiosis is commonly observed in patients with cirrhosis and chronic gastrointestinal
disorders; however, its effect on antitumor immunity in the liver is largely unknown. Here we …